Novartis Reports Results of MS Progression Discussion Tool in a Validation Study for Patients with Multiple Sclerosis

Shots:

• The Validation study involves assessing of MSProDiscuss in 198 patients with relapsing-remitting MS (RRMS), secondary progressive MS (SPMS) or a suspected transition to SPMS across the US, Canada & Germany
• The validation study resulted that MSProDiscuss can differentiate between RRMS and SPMS, utilizing information from the patient’s symptoms experienced in the 6mos., which were further converted into visual output through the algorithm providing physicians with better insights, presented at AAN’19
• MSProDiscuss is an algorithm-based tool, supporting & facilitating physicians & patients to evaluate the risk of transitioning RRMS to SPMS. The tool is housed on neuro-compass, the educational MS site, developed in collaboration with Adelphi Value with its expected WW availability in H1’20

Click here to read full press release/ article | Ref: Novartis | Image: Recruiting Blogs